Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required dosesCatharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinomaMarinda Meertens, Eline L Giraud, Esbar Hassan, et al.
International Journal of Cancer|January 11, 2021
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposureStefanie D Krens, Floor J E Lubberman, Marthe van Egmond, et al.
Therapeutic Drug Monitoring|August 25, 2022
Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and ToxicityRien H L Hoge, Suzan E H Detert Oude Weme, Walter L Vervenne, et al.
Pharmaceutical Research|January 9, 2019
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic StudyMarie-Rose B S Crombag, Aurelia H M de Vries Schultink, Stijn L W Koolen, et al.
Clinical Pharmacology and Therapeutics|May 25, 2019
The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study)Floor J E Lubberman, Hans Gelderblom, Paul Hamberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate CancerSofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2016
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical TrialTatiana C Schneider, Djoeke de Wit, Thera P Links, et al.
Therapeutic Drug Monitoring|October 1, 2019
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective StudyStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2020
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX studyLoek A W de Jong, Fortuné M K Elekonawo, Marie Lambert, et al.
Pageof 13